MovDisordV3, PascalFrancis, Corpus, bibRecord, 001F55

Three-dimensional gait biomechanics in Parkinson's disease: Evidence for a centrally mediated amplitude regulation disorder

Identifieur interne : 001F55 ( PascalFrancis/Corpus ); précédent : 001F54; suivant : 001F56

Three-dimensional gait biomechanics in Parkinson's disease: Evidence for a centrally mediated amplitude regulation disorder

Auteurs : Meg Morris ; Robert Iansek ; Jennifer Mcginley ; Thomas Matyas ; Frances Huxham

Source :

Movement disorders [ 0885-3185 ] ; 2005.

RBID : Pascal:05-0172411

Descripteurs français

Pascal (Inist)
- Système nerveux pathologie, Biomécanique, Amplitude, Parkinson maladie, Lévodopa, Traitement.

English descriptors

KwdEn :
- Amplitude, Biomechanics, Levodopa, Nervous system diseases, Parkinson disease, Treatment.

Abstract

We examined whether people with Parkinson's disease (PD) have a central amplitude regulation disorder using three-dimensional (3-D) gait analyses to compare the effects of medication and attentional strategies on gait in 12 PD subjects and 12 matched comparison subjects. Subjects with PD first performed several 10-m gait trials at preferred speed while off levodopa. They then walked at preferred speed on levodopa; off levodopa with cues; and on levodopa with cues. Control subjects walked at preferred speed and then with visual cues to match their stride length to PD values. As well as spatiotemporal footstep data, pelvic and lower limb kinematic profiles and angle-angle diagrams were produced for sagittal, coronal, and transverse plane movements using a 3-D motion analysis system. In people with PD, decreased step length was accompanied by reduced movement amplitude across all lower limb joints, in all movement planes. When control subjects were required to walk with short steps matched to the size of PD comparisons, they displayed a similar multijoint reduction in amplitude. For PD subjects, both levodopa and visual cues increased movement amplitude across all lower limb joints. Amplitude increased further when levodopa and visual cues were combined, resulting in normalization of step length. This finding suggested that reduced step length is due to a mismatch between cortically selected movement amplitude and basal ganglia maintenance mechanisms. Levodopa and cues normalized amplitude across all joints by altering motor set and bypassing defective basal ganglia mechanisms.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 20`
A06				`@2 1`
A08	`01`	`1`	`ENG`	`@1 Three-dimensional gait biomechanics in Parkinson's disease: Evidence for a centrally mediated amplitude regulation disorder`
A11	`01`	`1`		`@1 MORRIS (Meg)`
A11	`02`	`1`		`@1 IANSEK (Robert)`
A11	`03`	`1`		`@1 MCGINLEY (Jennifer)`
A11	`04`	`1`		`@1 MATYAS (Thomas)`
A11	`05`	`1`		`@1 HUXHAM (Frances)`
A14	`01`			`@1 School of Physiotherapy, Faculty of Health Sciences, La Trobe University @2 Melbourne, Victoria @3 AUS @Z 1 aut. @Z 2 aut. @Z 3 aut. @Z 5 aut.`
A14	`02`			`@1 Geriatric Research Unit, Kingston Centre, Southern Health @2 Cheltenham, Victoria @3 AUS @Z 2 aut. @Z 3 aut. @Z 5 aut.`
A14	`03`			`@1 School of Psychology, Faculty of Science and Technology, La Trobe University @2 Melbourne, Victoria @3 AUS @Z 4 aut.`
A20				`@1 40-50`
A21				`@1 2005`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000125001470050`
A44				`@0 0000 @1 © 2005 INIST-CNRS. All rights reserved.`
A45				`@0 44 ref.`
A47	`01`	`1`		`@0 05-0172411`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 We examined whether people with Parkinson's disease (PD) have a central amplitude regulation disorder using three-dimensional (3-D) gait analyses to compare the effects of medication and attentional strategies on gait in 12 PD subjects and 12 matched comparison subjects. Subjects with PD first performed several 10-m gait trials at preferred speed while off levodopa. They then walked at preferred speed on levodopa; off levodopa with cues; and on levodopa with cues. Control subjects walked at preferred speed and then with visual cues to match their stride length to PD values. As well as spatiotemporal footstep data, pelvic and lower limb kinematic profiles and angle-angle diagrams were produced for sagittal, coronal, and transverse plane movements using a 3-D motion analysis system. In people with PD, decreased step length was accompanied by reduced movement amplitude across all lower limb joints, in all movement planes. When control subjects were required to walk with short steps matched to the size of PD comparisons, they displayed a similar multijoint reduction in amplitude. For PD subjects, both levodopa and visual cues increased movement amplitude across all lower limb joints. Amplitude increased further when levodopa and visual cues were combined, resulting in normalization of step length. This finding suggested that reduced step length is due to a mismatch between cortically selected movement amplitude and basal ganglia maintenance mechanisms. Levodopa and cues normalized amplitude across all joints by altering motor set and bypassing defective basal ganglia mechanisms.
C02	`01`	`X`		`@0 002B17`
C02	`02`	`X`		`@0 002B17G`
C02	`03`	`X`		`@0 002B17A03`
C03	`01`	`X`	`FRE`	`@0 Système nerveux pathologie @5 01`
C03	`01`	`X`	`ENG`	`@0 Nervous system diseases @5 01`
C03	`01`	`X`	`SPA`	`@0 Sistema nervioso patología @5 01`
C03	`02`	`X`	`FRE`	`@0 Biomécanique @5 02`
C03	`02`	`X`	`ENG`	`@0 Biomechanics @5 02`
C03	`02`	`X`	`SPA`	`@0 Biomecánica @5 02`
C03	`03`	`X`	`FRE`	`@0 Amplitude @5 03`
C03	`03`	`X`	`ENG`	`@0 Amplitude @5 03`
C03	`03`	`X`	`SPA`	`@0 Amplitud @5 03`
C03	`04`	`X`	`FRE`	`@0 Parkinson maladie @5 04`
C03	`04`	`X`	`ENG`	`@0 Parkinson disease @5 04`
C03	`04`	`X`	`SPA`	`@0 Parkinson enfermedad @5 04`
C03	`05`	`X`	`FRE`	`@0 Lévodopa @2 NK @2 FR @5 05`
C03	`05`	`X`	`ENG`	`@0 Levodopa @2 NK @2 FR @5 05`
C03	`05`	`X`	`SPA`	`@0 Levodopa @2 NK @2 FR @5 05`
C03	`06`	`X`	`FRE`	`@0 Traitement @5 06`
C03	`06`	`X`	`ENG`	`@0 Treatment @5 06`
C03	`06`	`X`	`SPA`	`@0 Tratamiento @5 06`
C07	`01`	`X`	`FRE`	`@0 Encéphale pathologie @5 37`
C07	`01`	`X`	`ENG`	`@0 Cerebral disorder @5 37`
C07	`01`	`X`	`SPA`	`@0 Encéfalo patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Extrapyramidal syndrome @5 38`
C07	`02`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 38`
C07	`02`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 38`
C07	`03`	`X`	`FRE`	`@0 Maladie dégénérative @5 39`
C07	`03`	`X`	`ENG`	`@0 Degenerative disease @5 39`
C07	`03`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 39`
C07	`04`	`X`	`FRE`	`@0 Système nerveux central pathologie @5 40`
C07	`04`	`X`	`ENG`	`@0 Central nervous system disease @5 40`
C07	`04`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 40`
C07	`05`	`X`	`FRE`	`@0 Antiparkinsonien @5 41`
C07	`05`	`X`	`ENG`	`@0 Antiparkinson agent @5 41`
C07	`05`	`X`	`SPA`	`@0 Antiparkinsoniano @5 41`
N21				`@1 115`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 05-0172411 INIST
ET :	Three-dimensional gait biomechanics in Parkinson's disease: Evidence for a centrally mediated amplitude regulation disorder
AU :	MORRIS (Meg); IANSEK (Robert); MCGINLEY (Jennifer); MATYAS (Thomas); HUXHAM (Frances)
AF :	School of Physiotherapy, Faculty of Health Sciences, La Trobe University/Melbourne, Victoria/Australie (1 aut., 2 aut., 3 aut., 5 aut.); Geriatric Research Unit, Kingston Centre, Southern Health/Cheltenham, Victoria/Australie (2 aut., 3 aut., 5 aut.); School of Psychology, Faculty of Science and Technology, La Trobe University/Melbourne, Victoria/Australie (4 aut.)
DT :	Publication en série; Niveau analytique
SO :	Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2005; Vol. 20; No. 1; Pp. 40-50; Bibl. 44 ref.
LA :	Anglais
EA :	We examined whether people with Parkinson's disease (PD) have a central amplitude regulation disorder using three-dimensional (3-D) gait analyses to compare the effects of medication and attentional strategies on gait in 12 PD subjects and 12 matched comparison subjects. Subjects with PD first performed several 10-m gait trials at preferred speed while off levodopa. They then walked at preferred speed on levodopa; off levodopa with cues; and on levodopa with cues. Control subjects walked at preferred speed and then with visual cues to match their stride length to PD values. As well as spatiotemporal footstep data, pelvic and lower limb kinematic profiles and angle-angle diagrams were produced for sagittal, coronal, and transverse plane movements using a 3-D motion analysis system. In people with PD, decreased step length was accompanied by reduced movement amplitude across all lower limb joints, in all movement planes. When control subjects were required to walk with short steps matched to the size of PD comparisons, they displayed a similar multijoint reduction in amplitude. For PD subjects, both levodopa and visual cues increased movement amplitude across all lower limb joints. Amplitude increased further when levodopa and visual cues were combined, resulting in normalization of step length. This finding suggested that reduced step length is due to a mismatch between cortically selected movement amplitude and basal ganglia maintenance mechanisms. Levodopa and cues normalized amplitude across all joints by altering motor set and bypassing defective basal ganglia mechanisms.
CC :	002B17; 002B17G; 002B17A03
FD :	Système nerveux pathologie; Biomécanique; Amplitude; Parkinson maladie; Lévodopa; Traitement
FG :	Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative; Système nerveux central pathologie; Antiparkinsonien
ED :	Nervous system diseases; Biomechanics; Amplitude; Parkinson disease; Levodopa; Treatment
EG :	Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease; Antiparkinson agent
SD :	Sistema nervioso patología; Biomecánica; Amplitud; Parkinson enfermedad; Levodopa; Tratamiento
LO :	INIST-20953.354000125001470050
ID :	05-0172411

Links to Exploration step

Pascal:05-0172411

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Three-dimensional gait biomechanics in Parkinson's disease: Evidence for a centrally mediated amplitude regulation disorder</title>
<author><name sortKey="Morris, Meg" sort="Morris, Meg" uniqKey="Morris M" first="Meg" last="Morris">Meg Morris</name>
<affiliation><inist:fA14 i1="01"><s1>School of Physiotherapy, Faculty of Health Sciences, La Trobe University</s1>
<s2>Melbourne, Victoria</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Iansek, Robert" sort="Iansek, Robert" uniqKey="Iansek R" first="Robert" last="Iansek">Robert Iansek</name>
<affiliation><inist:fA14 i1="01"><s1>School of Physiotherapy, Faculty of Health Sciences, La Trobe University</s1>
<s2>Melbourne, Victoria</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Geriatric Research Unit, Kingston Centre, Southern Health</s1>
<s2>Cheltenham, Victoria</s2>
<s3>AUS</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Mcginley, Jennifer" sort="Mcginley, Jennifer" uniqKey="Mcginley J" first="Jennifer" last="Mcginley">Jennifer Mcginley</name>
<affiliation><inist:fA14 i1="01"><s1>School of Physiotherapy, Faculty of Health Sciences, La Trobe University</s1>
<s2>Melbourne, Victoria</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Geriatric Research Unit, Kingston Centre, Southern Health</s1>
<s2>Cheltenham, Victoria</s2>
<s3>AUS</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Matyas, Thomas" sort="Matyas, Thomas" uniqKey="Matyas T" first="Thomas" last="Matyas">Thomas Matyas</name>
<affiliation><inist:fA14 i1="03"><s1>School of Psychology, Faculty of Science and Technology, La Trobe University</s1>
<s2>Melbourne, Victoria</s2>
<s3>AUS</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Huxham, Frances" sort="Huxham, Frances" uniqKey="Huxham F" first="Frances" last="Huxham">Frances Huxham</name>
<affiliation><inist:fA14 i1="01"><s1>School of Physiotherapy, Faculty of Health Sciences, La Trobe University</s1>
<s2>Melbourne, Victoria</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Geriatric Research Unit, Kingston Centre, Southern Health</s1>
<s2>Cheltenham, Victoria</s2>
<s3>AUS</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">05-0172411</idno>
<date when="2005">2005</date>
<idno type="stanalyst">PASCAL 05-0172411 INIST</idno>
<idno type="RBID">Pascal:05-0172411</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001F55</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Three-dimensional gait biomechanics in Parkinson's disease: Evidence for a centrally mediated amplitude regulation disorder</title>
<author><name sortKey="Morris, Meg" sort="Morris, Meg" uniqKey="Morris M" first="Meg" last="Morris">Meg Morris</name>
<affiliation><inist:fA14 i1="01"><s1>School of Physiotherapy, Faculty of Health Sciences, La Trobe University</s1>
<s2>Melbourne, Victoria</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Iansek, Robert" sort="Iansek, Robert" uniqKey="Iansek R" first="Robert" last="Iansek">Robert Iansek</name>
<affiliation><inist:fA14 i1="01"><s1>School of Physiotherapy, Faculty of Health Sciences, La Trobe University</s1>
<s2>Melbourne, Victoria</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Geriatric Research Unit, Kingston Centre, Southern Health</s1>
<s2>Cheltenham, Victoria</s2>
<s3>AUS</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Mcginley, Jennifer" sort="Mcginley, Jennifer" uniqKey="Mcginley J" first="Jennifer" last="Mcginley">Jennifer Mcginley</name>
<affiliation><inist:fA14 i1="01"><s1>School of Physiotherapy, Faculty of Health Sciences, La Trobe University</s1>
<s2>Melbourne, Victoria</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Geriatric Research Unit, Kingston Centre, Southern Health</s1>
<s2>Cheltenham, Victoria</s2>
<s3>AUS</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Matyas, Thomas" sort="Matyas, Thomas" uniqKey="Matyas T" first="Thomas" last="Matyas">Thomas Matyas</name>
<affiliation><inist:fA14 i1="03"><s1>School of Psychology, Faculty of Science and Technology, La Trobe University</s1>
<s2>Melbourne, Victoria</s2>
<s3>AUS</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Huxham, Frances" sort="Huxham, Frances" uniqKey="Huxham F" first="Frances" last="Huxham">Frances Huxham</name>
<affiliation><inist:fA14 i1="01"><s1>School of Physiotherapy, Faculty of Health Sciences, La Trobe University</s1>
<s2>Melbourne, Victoria</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Geriatric Research Unit, Kingston Centre, Southern Health</s1>
<s2>Cheltenham, Victoria</s2>
<s3>AUS</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2005">2005</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Amplitude</term>
<term>Biomechanics</term>
<term>Levodopa</term>
<term>Nervous system diseases</term>
<term>Parkinson disease</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Système nerveux pathologie</term>
<term>Biomécanique</term>
<term>Amplitude</term>
<term>Parkinson maladie</term>
<term>Lévodopa</term>
<term>Traitement</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">We examined whether people with Parkinson's disease (PD) have a central amplitude regulation disorder using three-dimensional (3-D) gait analyses to compare the effects of medication and attentional strategies on gait in 12 PD subjects and 12 matched comparison subjects. Subjects with PD first performed several 10-m gait trials at preferred speed while off levodopa. They then walked at preferred speed on levodopa; off levodopa with cues; and on levodopa with cues. Control subjects walked at preferred speed and then with visual cues to match their stride length to PD values. As well as spatiotemporal footstep data, pelvic and lower limb kinematic profiles and angle-angle diagrams were produced for sagittal, coronal, and transverse plane movements using a 3-D motion analysis system. In people with PD, decreased step length was accompanied by reduced movement amplitude across all lower limb joints, in all movement planes. When control subjects were required to walk with short steps matched to the size of PD comparisons, they displayed a similar multijoint reduction in amplitude. For PD subjects, both levodopa and visual cues increased movement amplitude across all lower limb joints. Amplitude increased further when levodopa and visual cues were combined, resulting in normalization of step length. This finding suggested that reduced step length is due to a mismatch between cortically selected movement amplitude and basal ganglia maintenance mechanisms. Levodopa and cues normalized amplitude across all joints by altering motor set and bypassing defective basal ganglia mechanisms.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>20</s2>
</fA05>
<fA06><s2>1</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Three-dimensional gait biomechanics in Parkinson's disease: Evidence for a centrally mediated amplitude regulation disorder</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>MORRIS (Meg)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>IANSEK (Robert)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>MCGINLEY (Jennifer)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>MATYAS (Thomas)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>HUXHAM (Frances)</s1>
</fA11>
<fA14 i1="01"><s1>School of Physiotherapy, Faculty of Health Sciences, La Trobe University</s1>
<s2>Melbourne, Victoria</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Geriatric Research Unit, Kingston Centre, Southern Health</s1>
<s2>Cheltenham, Victoria</s2>
<s3>AUS</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>School of Psychology, Faculty of Science and Technology, La Trobe University</s1>
<s2>Melbourne, Victoria</s2>
<s3>AUS</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA20><s1>40-50</s1>
</fA20>
<fA21><s1>2005</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000125001470050</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2005 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>44 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>05-0172411</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>We examined whether people with Parkinson's disease (PD) have a central amplitude regulation disorder using three-dimensional (3-D) gait analyses to compare the effects of medication and attentional strategies on gait in 12 PD subjects and 12 matched comparison subjects. Subjects with PD first performed several 10-m gait trials at preferred speed while off levodopa. They then walked at preferred speed on levodopa; off levodopa with cues; and on levodopa with cues. Control subjects walked at preferred speed and then with visual cues to match their stride length to PD values. As well as spatiotemporal footstep data, pelvic and lower limb kinematic profiles and angle-angle diagrams were produced for sagittal, coronal, and transverse plane movements using a 3-D motion analysis system. In people with PD, decreased step length was accompanied by reduced movement amplitude across all lower limb joints, in all movement planes. When control subjects were required to walk with short steps matched to the size of PD comparisons, they displayed a similar multijoint reduction in amplitude. For PD subjects, both levodopa and visual cues increased movement amplitude across all lower limb joints. Amplitude increased further when levodopa and visual cues were combined, resulting in normalization of step length. This finding suggested that reduced step length is due to a mismatch between cortically selected movement amplitude and basal ganglia maintenance mechanisms. Levodopa and cues normalized amplitude across all joints by altering motor set and bypassing defective basal ganglia mechanisms.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17G</s0>
</fC02>
<fC02 i1="03" i2="X"><s0>002B17A03</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Biomécanique</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Biomechanics</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Biomecánica</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Amplitude</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Amplitude</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Amplitud</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Lévodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Levodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Levodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Traitement</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Treatment</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>06</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Antiparkinsonien</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Antiparkinson agent</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Antiparkinsoniano</s0>
<s5>41</s5>
</fC07>
<fN21><s1>115</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 05-0172411 INIST</NO>
<ET>Three-dimensional gait biomechanics in Parkinson's disease: Evidence for a centrally mediated amplitude regulation disorder</ET>
<AU>MORRIS (Meg); IANSEK (Robert); MCGINLEY (Jennifer); MATYAS (Thomas); HUXHAM (Frances)</AU>
<AF>School of Physiotherapy, Faculty of Health Sciences, La Trobe University/Melbourne, Victoria/Australie (1 aut., 2 aut., 3 aut., 5 aut.); Geriatric Research Unit, Kingston Centre, Southern Health/Cheltenham, Victoria/Australie (2 aut., 3 aut., 5 aut.); School of Psychology, Faculty of Science and Technology, La Trobe University/Melbourne, Victoria/Australie (4 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2005; Vol. 20; No. 1; Pp. 40-50; Bibl. 44 ref.</SO>
<LA>Anglais</LA>
<EA>We examined whether people with Parkinson's disease (PD) have a central amplitude regulation disorder using three-dimensional (3-D) gait analyses to compare the effects of medication and attentional strategies on gait in 12 PD subjects and 12 matched comparison subjects. Subjects with PD first performed several 10-m gait trials at preferred speed while off levodopa. They then walked at preferred speed on levodopa; off levodopa with cues; and on levodopa with cues. Control subjects walked at preferred speed and then with visual cues to match their stride length to PD values. As well as spatiotemporal footstep data, pelvic and lower limb kinematic profiles and angle-angle diagrams were produced for sagittal, coronal, and transverse plane movements using a 3-D motion analysis system. In people with PD, decreased step length was accompanied by reduced movement amplitude across all lower limb joints, in all movement planes. When control subjects were required to walk with short steps matched to the size of PD comparisons, they displayed a similar multijoint reduction in amplitude. For PD subjects, both levodopa and visual cues increased movement amplitude across all lower limb joints. Amplitude increased further when levodopa and visual cues were combined, resulting in normalization of step length. This finding suggested that reduced step length is due to a mismatch between cortically selected movement amplitude and basal ganglia maintenance mechanisms. Levodopa and cues normalized amplitude across all joints by altering motor set and bypassing defective basal ganglia mechanisms.</EA>
<CC>002B17; 002B17G; 002B17A03</CC>
<FD>Système nerveux pathologie; Biomécanique; Amplitude; Parkinson maladie; Lévodopa; Traitement</FD>
<FG>Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative; Système nerveux central pathologie; Antiparkinsonien</FG>
<ED>Nervous system diseases; Biomechanics; Amplitude; Parkinson disease; Levodopa; Treatment</ED>
<EG>Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease; Antiparkinson agent</EG>
<SD>Sistema nervioso patología; Biomecánica; Amplitud; Parkinson enfermedad; Levodopa; Tratamiento</SD>
<LO>INIST-20953.354000125001470050</LO>
<ID>05-0172411</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001F55 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 001F55 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:05-0172411
   |texte=   Three-dimensional gait biomechanics in Parkinson's disease: Evidence for a centrally mediated amplitude regulation disorder
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Three-dimensional gait biomechanics in Parkinson's disease: Evidence for a centrally mediated amplitude regulation disorder

Three-dimensional gait biomechanics in Parkinson's disease: Evidence for a centrally mediated amplitude regulation disorder

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri